{"id":"W2099752220","doi":"10.1200/jco.2008.21.4809","title":"Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2130,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Bevacizumab; Sorafenib; Proportional hazards model; Cohort; Adverse effect; Oncology; Vascular endothelial growth factor; Cancer; Gastroenterology; Hepatocellular carcinoma; Chemotherapy; VEGF receptors","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}